|
|
HHSN292201500060U
|
$5,878,180
|
N/A
|
CONSTELLATION NEW ENERGY
|
|
(2/2) Howard University/Johns Hopkins Partnership in HPV-Related Cancer Research
|
5P20CA192988-04
|
$179,686
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
(9) Biophysical Description of Age and Dose Dependent Changes to Dendritic Morphology that Impact Cognition following Radiation Cancer Therapy
|
5R01CA208526-02
|
$472,047
|
CUCINOTTA, FRANCIS
|
UNIVERSITY OF NEVADA LAS VEGAS
|
|
(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics
|
1R01CA215802-01
|
$503,309
|
SPARREBOOM, ALEXANDER
|
OHIO STATE UNIVERSITY
|
|
(Diversity supplement to R01CA188096) Targeting autophagaphy in hereditary breast cancer
|
3R01CA188096-03S1
|
$57,707
|
XIA, BING
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
(PQ 5) Roles of mitochondrial heterogeneity in cell survival and oncogenesis
|
1R21CA216304-01
|
$234,900
|
NEWMEYER, DONALD
|
LA JOLLA INST FOR ALLERGY & IMMUNOLGY
|
|
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
|
1R01CA205965-01A1
|
$650,815
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy
|
1R01CA219866-01
|
$445,407
|
DIANTONIO, AARON
|
WASHINGTON UNIVERSITY
|
|
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
|
5R01CA205954-02
|
$438,499
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
(PQ1) Identifying and targeting human glioblastoma migrating in the peritumoral niche
|
1R01CA216054-01
|
$324,411
|
HAYDEN, MELANIE
|
STANFORD UNIVERSITY
|
|
(PQ1) Lipid Metabolism, Inflammation, and T cell Dysfunction in HIV-associated Cancer
|
1R01CA206483-01A1
|
$718,958
|
EMU, BRINDA
|
YALE UNIVERSITY
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
5R21CA205644-02
|
$202,439
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
(PQ2) HIV INFECTION, APOBEC UPREGULATION, AND CANCER MUTAGENESIS
|
5R21CA206309-02
|
$182,192
|
HARRIS, REUBEN
|
UNIVERSITY OF MINNESOTA
|
|
(PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expression
|
1R01CA220009-01
|
$310,000
|
ZANETTI, MAURIZIO
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
5R01CA206476-02
|
$772,521
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes
|
1R01CA216265-01
|
$632,860
|
CHRISTENSEN, BROCK
|
DARTMOUTH COLLEGE
|
|
(PQ3) Immune Modulation of DNA Mismatch Repair in Colorectal Cancer
|
5R01CA206010-02
|
$369,639
|
CARETHERS, JOHN
|
UNIVERSITY OF MICHIGAN
|
|
(PQ4A) Metabolic Plasticity of Pre-Malignant Cells During Tumor Progression
|
3R01CA194461-03S1
|
$57,872
|
PARK, KWON-SIK
|
UNIVERSITY OF VIRGINIA
|
|
(PQ4A) Metabolic Plasticity of Pre-Malignant Cells During Tumor Progression
|
5R01CA194461-03
|
$334,552
|
PARK, KWON-SIK
|
UNIVERSITY OF VIRGINIA
|
|
(PQ5) Consequences of imbalanced mitophagy and mitochondrial biogenesis in cancer
|
1R01CA216242-01
|
$318,277
|
MACLEOD, KAY
|
UNIVERSITY OF CHICAGO
|
|
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa
|
1R01CA217138-01
|
$644,421
|
WARREN, EDUS
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
|
5R01CA208642-02
|
$352,275
|
SHACKELFORD, DAVID
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQ5) Informing anal neoplasia differences/similarities in HIV-serodiscordant individuals
|
1R21CA216830-01
|
$231,000
|
SHIRAMIZU, BRUCE
|
UNIVERSITY OF HAWAII AT MANOA
|
|
(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition
|
5R01CA206012-02
|
$402,548
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression
|
5R01CA205975-02
|
$386,619
|
GHAFFARI, SAGHI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ5) Role of HIV-associated cellular miRNAs in HPV 16-induced pathogenesis
|
5R21CA206352-02
|
$198,125
|
PALEFSKY, JOEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ5) Role of Mitochondrial Division in Cancer Biology
|
5R01CA206005-02
|
$351,209
|
CHIPUK, JERRY
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
|
5R01CA205632-02
|
$457,974
|
RIEGEL, ANNA
|
GEORGETOWN UNIVERSITY
|
|
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy
|
5R01CA206028-02
|
$342,964
|
GEWIRTZ, DAVID
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQA2) Interstitial stiffness as a physicochemical modulator of obesity-induced b
|
5R01CA185293-04
|
$329,104
|
FISCHBACH, CLAUDIA
|
CORNELL UNIVERSITY
|
|
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause
|
5R01CA185530-04
|
$367,275
|
MOSES, MARSHA
|
BOSTON CHILDREN'S HOSPITAL
|
|
(PQA4) Molecularly Targeted Chemoprevention for Preneoplastic Squamous (5R01 CA194617-02)
|
5R01CA194617-04
|
$412,607
|
TSAI, KENNETH
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
(PQA5) 'Dose and Mechanisms of Exercise in Breast Cancer Prevention'
|
5R01CA179992-04
|
$909,181
|
JONES, LEE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma
|
5R01CA183776-05
|
$309,175
|
LESSNICK, STEPHEN
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development
|
5R01CA184926-04
|
$765,544
|
JAFFEE, ELIZABETH
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQB3) CD4 T cell response to BCR-ABL-positive Leukemia
|
5R01CA185062-04
|
$312,304
|
FARRAR, MICHAEL
|
UNIVERSITY OF MINNESOTA
|
|
(PQB3) Investigating innate immunosurveillance of oncogene-induced danger signals
|
5R01CA185020-04
|
$325,181
|
JACKS, TYLER
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
(PQB4) Stochastic Profiling of Functional Single-Cell States Within Solid Tumors
|
5R01CA194470-03
|
$446,627
|
JANES, KEVIN
|
UNIVERSITY OF VIRGINIA
|
|
(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic Data
|
5R01CA185486-04
|
$517,690
|
RABADAN, RAUL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
(PQB5)Molecular Wiring and Therapeutic Targeting of EGFR and PDGFR Signaling Netw
|
5R01CA185137-04
|
$882,372
|
CHAREST, ALAIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
(PQC2) Localization as a determinant of cancer dormancy
|
5R01CA194596-03
|
$553,740
|
LIN, CHARLES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
(PQC2)Nanoscale changes in 3D nuclear architecture during breast tumorigenesis
|
5R01CA185363-04
|
$318,250
|
LIU, YANG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
(PQC6) Molecular Determinants of Quiescent Cancer Cells
|
5R01CA185086-04
|
$423,327
|
VASUDEVAN, SHOBHA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
(PQD-1) Selective pressure of antiandrogens on castration resistant prostate canc
|
5R01CA185509-04
|
$258,128
|
GHOSH, PARAMITA
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
(PQD-3) Spatiotemporal Molecular Interrogation of Early Metastatic Evolution In Situ
|
5R01CA194697-03
|
$347,700
|
ZHANG, SIYUAN
|
UNIVERSITY OF NOTRE DAME
|
|
(PQD-5) Patient derived orthotopic xenograft models for drug response prediction
|
5R01CA185402-04
|
$318,923
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQD1) An Iterative Approach for Overcoming Evolving Targeted Therapy Resistance
|
5R01CA185404-04
|
$328,888
|
WU, LANI
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma
|
5R01CA185072-04
|
$348,312
|
SEKULIC, ALEKSANDAR
|
MAYO CLINIC ARIZONA
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-04
|
$613,546
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
5R01CA184922-04
|
$553,684
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|